Critical targets came out of that work, among them SRC and the PIK3CA, PIK3CB and PIK3CD genes, CYP3A4 and IGF1R, ESR1 and KDR. These bear on the control of oxidative stress, on cell growth, on endocrine resistance and on the progress of cancer.
Deciphering the Anticancer Mechanism of Naringenin and Berberine in Breast Cancer via Network Pharmacology and Molecular Docking
Shaikh Mo Sarosh, Shaikh Moin, Shaikh Mehmood Dawood
- Editor approved · 16 Nov 2026
- June 2026
- DOI 10.56511/jipbs.2026.13104
The question
What therapeutic potential do Naringenin and Berberine show against breast cancer, and at which targets?
- Breast cancer is among the commonest malignancies in women around the world and still a leading cause of illness and death from cancer.
- Despite advances in conventional therapy, resistance to drugs, toxicity through the body and poor selectivity keep limiting how well it works.
- Safer molecules from natural sources able to act on several targets have therefore drawn much scientific interest.
What was done
- Network pharmacology and molecular docking were used together to examine what the two compounds might do against breast cancer.
- Likely targets of the compounds were found with SwissTargetPrediction and PubChem; the genes tied to breast cancer were sought in the GeneCards database.
- Protein-protein interaction analysis and studies of pathway enrichment followed.
Key findings
Berberine's docking score at SRC was -6.6 kcal/mol, and at PIK3CA -6.2 kcal/mol.
Naringenin's scores were -5.8 kcal/mol at SRC and -6.9 kcal/mol at PIK3CA, set beside the reference medication Alpelisib.
The docking work showed favorable binding interactions for both compounds with SRC (7A3D) and with PIK3CA (2V1Y).
Why it matters
- The authors say the data point to anticancer potential for these plant chemicals against breast cancer, through action at several targets.
- The work joined network pharmacology to molecular docking, which gave the binding at SRC and PIK3CA.
How to cite
Shaikh Mo Sarosh, Shaikh Moin, Shaikh Mehmood Dawood. Deciphering the Anticancer Mechanism of Naringenin and Berberine in Breast Cancer via Network Pharmacology and Molecular Docking. Journal of Innovations in Pharmaceutical and Biological Sciences. 2026;13(01):24-34. https://doi.org/10.56511/jipbs.2026.13104
- The article at doi.org (the publisher's page and PDF)
- The article on the journal's site
- The journal at the ISSN Portal (ISSN 2349-2759)